ArticleAntimicrobial agents and chemotherapy2010
Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.
Article in Antimicrobial agents and chemotherapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 115 citations in OpenAlex.
- Xenodiagnosis to Search for Borrelia burgdorferi After Antibiotic Treatment of Lyme Disease: A Prospective Cohort Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Trial
- Evaluation of Immune Response Dynamics: Analyzing the Parameters of Complete Blood Count (CBC) in Experimental Borreliosis.Life (Basel, Switzerland) · 2025Article
- Concurrent Infection of the Human Brain with MultipleInternational journal of molecular sciences · 2023Article
- Can mesenchymal stem/stromal cells and their secretomes combat bacterial persisters?World journal of microbiology & biotechnology · 2023Review
- Lyme borreliosis diagnosis: state of the art of improvements and innovations.BMC microbiology · 2023Review
- The Use of Natural Bioactive Nutraceuticals in the Management of Tick-Borne Illnesses.Microorganisms · 2023Review
- Superior efficacy of combination antibiotic therapy versus monotherapy in a mouse model of Lyme disease.Frontiers in microbiology · 2023Article
- Lyme disease and the pursuit of a clinical cure.Frontiers in medicine · 2023Review
- Persistent Borrelia burgdorferiClinical microbiology reviews · 2022Review
- Review
- Recent Progress in Lyme Disease and Remaining Challenges.Frontiers in medicine · 2021Review
- Detecting Borrelia Spirochetes: A Case Study With Validation Among Autopsy Specimens.Frontiers in neurology · 2021Article
- Dermatological and Genital Manifestations of Lyme Disease Including Morgellons Disease.Clinical, cosmetic and investigational dermatology · 2021Article
- Repurposing Disulfiram (Tetraethylthiuram Disulfide) as a Potential Drug Candidate againstAntibiotics (Basel, Switzerland) · 2020Article
- Article
- Bacteriostatic and Bactericidal Effect of Tigecycline onAntibiotics (Basel, Switzerland) · 2020Article
- Chronic Lyme Disease: An Evidence-Based Definition by the ILADS Working Group.Antibiotics (Basel, Switzerland) · 2019Article
- Potential Persistent Borrelia Infection and Response to Antibiotic Therapy; a Clinical Case Study and Review of Recent Literature.Antibiotics (Basel, Switzerland) · 2019Article
- The Long-Term Persistence ofAntibiotics (Basel, Switzerland) · 2019Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The effectiveness of a new first-in-class antibiotic, tigecycline (glycylcycline), was evaluated during the early dissemination (1 week), early immune (3 weeks), or late persistent (4 months) phases of Borrelia burgdorferi infection in C3H mice. Mice were treated with high or low doses of tigecycline, saline (negative-effect controls), or a previously published regimen of ceftriaxone (positive-effect controls). Infection status was assessed at 3 months after treatment by culture, quantitative ospA real-time PCR, and subcutaneous transplantation of joint and heart tissue into SCID mice. Tissues from all saline-treated mice were culture and ospA PCR positive, tissues from all antibiotic-treated mice were culture negative, and some of the tissues from most of the mice treated with antibiotics were ospA PCR positive, although the DNA marker load was markedly decreased compared to that in saline-treated mice. Antibiotic treatment during the early stage of infection appeared to be more effective than treatment that began during later stages of infection. The viability of noncultivable spirochetes in antibiotic-treated mice (demonstrable by PCR) was confirmed by transplantation of tissue allografts from treated mice into SCID mice, with dissemination of spirochetal DNA to multiple recipient tissues, and by xenodiagnosis, including acquisition by ticks, transmission by ticks to SCID mice, and survival through molting into nymphs and then into adults. Furthermore, PCR-positive heart base tissue from antibiotic-treated mice revealed RNA transcription of several B. burgdorferi genes. These results extended previous studies with ceftriaxone, indicating that antibiotic treatment is unable to clear persisting spirochetes, which remain viable and infectious, but are nondividing or slowly dividing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.